Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation After Coronary Stent Implantation

  • Jang, Sung-Won (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Rho, Tai-Ho (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Kim, Dong-Bin (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Cho, Eun-Joo (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Kwon, Beom-June (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Park, Hun-Jun (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Shin, Woo-Seung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Kim, Ji-Hoon (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Lee, Jong-Min (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Moon, Keon-Woong (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Oh, Yong-Seog (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Yoo, Ki-Dong (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Youn, Ho-Joong (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Lee, Man-Young (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Chung, Wook-Sung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Seung, Ki-Bae (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine) ;
  • Kim, Jae-Hyung (Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine)
  • Published : 2011.10.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Little evidence is available on the optimal antithrombotic therapy following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF). We investigated the outcomes of antithrombotic treatment strategies in AF patients who underwent PCI. Subjects and Methods: Three hundred sixty-two patients (68.0% men, mean age: 68.3${\pm}$7.8 years) with AF and who had undergone PCI with stent implantation between 2005 and 2007 were enrolled. The clinical, demographic and procedural characteristics were reviewed and the stroke risk factors as well as antithrombotic regimens were analyzed. Results: The accompanying comorbidities were as follows: hypertension (59.4%), diabetes (37.3%) and congestive heart failure (16.6%). The average number of stroke risk factors was 1.6. At the time of discharge after PCI, warfarin was prescribed for 84 patients (23.2%). Cilostazol was used in addition to dual antiplatelet therapy in 35% of the patients who did not receive warfarin. The mean follow-up period was 615${\pm}$385 days. The incidences of major adverse cardiac events (MACE), stroke and major bleeding were 11.3%, 3.6% and 4.1%, respectively. By Kaplan-Meier survival analysis, warfarin treatment was not associated with a lower risk of MACE (p=0.886), but it was associated with an increased risk of major bleeding (p=0.002). Conclusion: Oral anticoagulation therapy after PCI may increase hemorrhagic events in Korean AF patients.

Keywords

References

  1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906. https://doi.org/10.1016/j.jacc.2006.07.009
  2. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. https://doi.org/10.1001/jama.288.19.2441
  3. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007:CD006186.
  4. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-7. https://doi.org/10.1378/chest.130.6.1823
  5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. https://doi.org/10.1001/jama.285.22.2864
  6. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-25. https://doi.org/10.1016/j.jacc.2007.11.035
  7. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-8. https://doi.org/10.1016/j.amjcard.2007.05.032
  8. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9. https://doi.org/10.1016/j.ahj.2009.01.006
  9. Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J 2009;39:462-6. https://doi.org/10.4070/kcj.2009.39.11.462
  10. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12. https://doi.org/10.1016/S0140-6736(06)68845-4
  11. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-37. https://doi.org/10.1161/CIRCULATIONAHA.107.750000
  12. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-74. https://doi.org/10.1016/S0140-6736(09)61751-7
  13. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-15. https://doi.org/10.1016/j.jacc.2007.01.098
  14. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007;71:761-5. https://doi.org/10.1253/circj.71.761
  15. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8. https://doi.org/10.1001/jama.287.13.1690
  16. Li T, Lange LA, Li X, et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006;43:740-4. https://doi.org/10.1136/jmg.2005.040410
  17. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93. https://doi.org/10.1056/NEJMoa044503

Cited by

  1. Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis vol.10, pp.None, 2012, https://doi.org/10.1186/1477-9560-10-22
  2. Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review vol.38, pp.3, 2011, https://doi.org/10.1007/s11239-014-1094-1
  3. Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation vol.29, pp.5, 2011, https://doi.org/10.1007/s00380-013-0399-x
  4. Q10 supplementation effects on cardiac enzyme CK-MB and troponin in patients undergoing coronary artery bypass graft: a randomized, double-blinded, placebo-controlled clinical trial vol.8, pp.1, 2011, https://doi.org/10.15171/jcvtr.2016.01
  5. Diagnosis and management of acute coronary syndrome vol.60, pp.7, 2011, https://doi.org/10.5124/jkma.2017.60.7.568
  6. Antithrombotic Regimens in Patients With Percutaneous Coronary Intervention Whom an Anticoagulant Is Indicated: A Systematic Review and Network Meta-Analysis vol.9, pp.None, 2011, https://doi.org/10.3389/fphar.2018.01322